Cost-effectiveness analysis of lung cancer screening with low-dose computed tomography in an Iranian high-risk population

2021 ◽  
pp. 096914132110182
Author(s):  
Mansur Haji Esmaeili ◽  
Farshad Seyednejad ◽  
Alireza Mahboub-Ahari ◽  
Hossein Ameri ◽  
Hadi Abdollahzad ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Cost Effectiveness ◽  
High Risk ◽  
Low Dose ◽  
High Risk Population ◽  
Risk Population ◽  
System Perspective ◽  
The Cost ◽  
Low Dose Computed Tomography

Objective The results of recent studies have shown that using low-dose computed tomography (LDCT) for screening of lung cancer (LC) improves cancer outcomes. The objective of the current study was to evaluate the cost-effectiveness of LDCT in an Iranian high-risk population. Methods A Markov cohort simulation model with four health states was used to evaluate the cost-effectiveness of LDCT from a healthcare system perspective in the people aged 55–74 who smoked 25 or more cigarettes per day for 10–30 years. Cost data were collected, reviewing 324 medical records of patients with LC, and utilities and transition probabilities were extracted from the literature. The Monte Carlo simulation method was applied to run the model. Probabilistic sensitivity analysis and one-way analysis were also performed. Results LC screening in comparison to a no-screening strategy was costly and effective. The incremental cost-effectiveness ratio of screening versus no-screening was IRR (Iranian rials) 98,515,014.04 which falls below the Iranian threshold of three times GDP (gross domestic product) per capita. One-way and probabilistic sensitivity analyses demonstrated that the results of the economic analysis were robust to variations in the key inputs for both. Conclusions Using LDCT for screening of LC patients in a high-risk population is a cost-effective strategy.

scholarly journals Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia

2018 ◽  
Vol 13 (8) ◽  
pp. 1094-1105 ◽  
Author(s):  
Stephen Wade ◽  
Marianne Weber ◽  
Michael Caruana ◽  
Yoon-Jung Kang ◽  
Henry Marshall ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
High Risk ◽  
Low Dose ◽  
Lung Cancer Screening ◽  
The Cost ◽  
Low Dose Computed Tomography

scholarly journals Az alacsony dózisú CT-vel végzett tüdőrákszűrés magyarországi egészség-gazdaságtani elemzésének koncepcionális terve

2017 ◽  
Vol 158 (25) ◽  
pp. 963-975
Author(s):  
Zoltán Vokó ◽  
Magdolna Barra ◽  
Anett Molnár ◽  
Anna Kerpel-Fronius ◽  
Gábor Bajzik ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Low Dose ◽  
Health Economic Evaluation ◽  
Lung Cancer Screening ◽  
Patient Pathways ◽  
The Cost ◽  
Low Dose Computed Tomography

Abstract: Introduction: Lung cancer is a rapidly progressing, often life-threatening disease that constitutes a huge societal burden. Because of the scarce resources of the Hungarian health care system, the cost-effectiveness of introducing low-dose computed tomography screening is a relevant health policy matter. Aim: The aim of this study is to design a model concept for assessing the cost-effectiveness of low-dose computed tomography lung cancer screening in Hungary, and to define the required steps for performing the analysis. Method: A targeted literature review was conducted to identify and synthesize the evidence on efficacy and effectiveness of screening, and results were evaluated based on adaptability to Hungarian settings. We also summarized the available Hungarian scientific evidence and reconstructed the potential patient pathways. Results: In accordance with these findings, we recommend to perform the full health-economic evaluation of low-dose computed tomography lung cancer screening using a complex model structure that consists of several sub-models and is capable to follow the population at risk on life-time horizon. Conclusions: The proposed cost-effectiveness model will be suitable to provide data for further analyses that support decision-making on introducing low-dose computed tomography lung cancer screening as public health program. Orv Hetil. 2017; 158(25): 963–975.

scholarly journals Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study

2020 ◽  
Vol 135 ◽  
pp. 121-129 ◽  
Author(s):  
Yihui Du ◽  
Grigory Sidorenkov ◽  
Marjolein A. Heuvelmans ◽  
Harry J.M. Groen ◽  
Karin M. Vermeulen ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Low Dose ◽  
Lung Cancer Screening ◽  
Low Dose Computed Tomography ◽  
Heavy Smokers ◽  
Modelling Study

scholarly journals Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the UK

Open Heart ◽  
2019 ◽  
Vol 6 (1) ◽  
pp. e001037 ◽  
Author(s):  
Claudia I Rinciog ◽  
Laura M Sawyer ◽  
Alexander Diamantopoulos ◽  
Mitchell S V Elkind ◽  
Matthew Reynolds ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
High Risk ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Sensitivity Analyses ◽  
High Risk Population ◽  
Risk Population ◽  
Life Years ◽  
The Uk ◽  
The Cost

ObjectiveTo evaluate the cost-effectiveness of insertable cardiac monitors (ICMs) compared with standard of care (SoC) for detecting atrial fibrillation (AF) in patients at high risk of stroke (CHADS2 >2), using a UK National Health Service (NHS) perspective.MethodsUsing patient characteristics and clinical data from the REVEAL AF trial, a Markov model assessed the cost-effectiveness of detecting AF with an ICM compared with SoC. Costs and benefits were extrapolated across modelled patient lifetime. Ischaemic and haemorrhagic strokes, intracranial and extracranial haemorrhages and minor bleeds were modelled. Diagnostic and device costs were included, plus costs of treating stroke and bleeding events and costs of oral anticoagulants (OACs). Costs and health outcomes, measured as quality-adjusted life years (QALYs), were discounted at 3.5% per annum. One-way deterministic and probabilistic sensitivity analyses (PSA) were undertaken.ResultsThe total per-patient cost for ICM was £13 360 versus £11 936 for SoC (namely, annual 24 hours Holter monitoring). ICMs generated a total of 6.50 QALYs versus 6.30 for SoC. The incremental cost-effectiveness ratio (ICER) was £7140/QALY gained, below the £20 000/QALY acceptability threshold. ICMs were cost-effective in 77.4% of PSA simulations. The number of ICMs needed to prevent one stroke was 21 and to cause a major bleed was 37. ICERs were sensitive to assumed proportions of patients initiating or discontinuing OAC after AF diagnosis, type of OAC used and how intense the traditional monitoring was assumed to be under SoC.ConclusionsThe use of ICMs to identify AF in a high-risk population is cost-effective for the UK NHS.

scholarly journals Cost-effectiveness analysis of low-dose computed tomography screening for lung cancer in Hungary

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
Z Voko ◽  
A Molnar ◽  
V Valay ◽  
M Moizs ◽  
A Kerpel-Fronius ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Low Dose ◽  
Screening Programme ◽  
Risk Group ◽  
Lung Cancer Screening ◽  
Cost Effective ◽  
Low Dose Computed Tomography

Abstract Background Hungary has the highest incidence of lung cancer in the world (GLOBOCAN, 2018). Since lung cancer is rarely treatable in its advanced stage, one possible way to reduce mortality is early diagnosis and subsequent treatment. The possibility and necessity of introducing low-dose computed tomography (LDCT) lung cancer screening as a public health programme is a current and relevant health policy issue. Methods A Markov cohort model was built to assess the cost-effectiveness of such a risk group screening programme in Hungary. The model was populated with transition probabilities and resource utilization data derived from the HUNCHEST Hungarian lung cancer screening trial. The model results are presented in incremental cost-effectiveness ratio. Results A closed cohort of 10,000 smokers with the average starting age of 59 years was followed over life-time horizon and screened for lung cancer annually until the age of 74. Compared to the current scenario of no organized lung cancer screening in Hungary, the model resulted in an additional 0.1614 life-year gained per individual and an additional 0.2924 disease-free life-year gained per individual with annual screening frequency. The incremental cost-effectiveness ratio was EUR 608 indicating that assessed intervention is cost-effective in the analyzed setting. Sensitivity analyses confirmed the robustness of the model results. Conclusions Results suggest that introducing low-dose computed tomography screening for lung cancer is a cost-effective intervention in Hungary. Considering the exceptionally high incidence and mortality of lung cancer in Hungary, the population could benefit from such a risk group screening programme. Key messages Low-dose computed tomography screening for lung cancer is cost-effectiveness in the Hungarian setting. Policy makers are encouraged to consider the introduction of a risk group screening programme.

Sign in / Sign up

Export Citation Format

Share Document